PRAH
PRA Health Sciences Inc
PRA Health Sciences Inc historical holders
total: 1
Pzena Investment Management PRA Health Sciences Inc transactions over time
- Total transactions:
- 4
- New positions:
- 2
- Sold out:
- 2
- Held since:
- 2021 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q3
Richard Pzena has been an institutional investor in PRA Health Sciences Inc (PRAH) since 2018 Q2. According to 2026 Q1 report, Richard Pzena doesn't hold any shares. The fund/company first acquired PRAH in 2018 Q2, initially purchasing 5,583 shares. Richard Pzena later completely sold out the position and reinvested in PRAH again in 2021 Q2. Since the initial investment, Pzena Investment Management has made 3 more transactions in this position.
When did Richard Pzena exit their PRAH position?
Richard Pzena no longer holds PRA Health Sciences Inc (PRAH). They sold off their entire position in 2021 Q3, closing out an investment that began in 2018 Q2.
When did Richard Pzena first invest in PRAH?
Richard Pzena first invested in PRA Health Sciences Inc (PRAH) in 2018 Q2 at the reported quarter-end price of $93.32 per share, acquiring 5,583 shares in their initial purchase.
What is Richard Pzena's average cost basis for PRAH?
Based on historical transaction data, Richard Pzena's estimated cost basis for PRA Health Sciences Inc (PRAH) is approximately $165.19 per share. This represents their average reported price* across all buy transactions.
Has Richard Pzena reinvested in PRAH after selling?
Yes, Richard Pzena has shown renewed interest in PRA Health Sciences Inc (PRAH). After completely selling their position, they reinitiated an investment in 2021 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $165.19
- Weighted AVG sell price:
- $165.19
PRAH transactions history by Pzena Investment Management
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q3
|
0.00%
|
0
|
$165.19
|
|
-100% (-3,378)
|
-0%
|
|
2021 Q2
|
0.00%
|
3,378
|
$165.19
|
$558,000
|
new
|
+0%
|
|
2018 Q3
|
0.00%
|
$93.32
|
-100% (-5,583)
|
|||
|
2018 Q2
|
0.00%
|
$93.32
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.